Clinical trial
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or…
NCT00085293 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00085293 |
|---|---|
| Title | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 |
| Official title | Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography |
| Enrollment | 12 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Jun 11, 2004 |
| Last update posted | Nov 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: